Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy

NARecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

March 10, 2013

Primary Completion Date

March 10, 2026

Study Completion Date

December 10, 2027

Conditions
Primary IgA-nephropathyHigh-riskCaucasians
Interventions
DRUG

Immunosuppressive treatment

"Patients will be able to receive the corticosteroid (CS) monotherapy or CS in combination with other immunosuppressive drugs (e.g. cyclophosphamide, mycophenolic acid) by a decision of treating physician.~CS treatment will start with intravenous or oral induction. In the first case, methylprednisolone will be administered intravenously for 1-3 days at the dosage of 500-1000 mg. Oral prednisolone will be initiated at a dose of 0.5 to 1.0 mg/kg body weight, not exceeded 60 mg/day (week 1) with a rapid decrease by 5 mg each subsequent week until a maintenance dose of 5 mg/day will be reached. Patients will receive maintenance dose for 6 to 12 months."

PROCEDURE

Tonsillectomy

Tonsillectomy will be done in accordance with local clinical practice. TE has to be performed no earlier than 12 months before and no later than 12 months after the initiation of IST.

Trial Locations (2)

197022

RECRUITING

Research Institute of Nephrology (Pavlov Medical University), Saint Petersburg

RECRUITING

St. Petersburg State Pavlov Medical University, Saint Petersburg

All Listed Sponsors
lead

St. Petersburg State Pavlov Medical University

OTHER